Literature DB >> 2050180

Kinetics of intravenous metoclopramide in patients with hepatic cirrhosis.

F Albani1, M R Tamè, R De Palma, M Bernardi.   

Abstract

The pharmacokinetics of metoclopramide has been studied after acute IV administration to 12 patients with hepatic cirrhosis (6 with and 6 without ascites) and 6 control subjects. The elimination half-life was significantly longer in patients (11.4 h and 9.9 h in those with and without ascites, respectively, vs 6.4 h in controls). Total plasma clearance was significantly lower in patients (0.29 and 0.36 l.kg-1.h-1 vs 0.52 l.kg-1.h-1 in controls). The differences between patients with and without ascites did not reach statistical significance. Reduction of functional hepatic blood flow in cirrhotic patients is the probable cause of the observed alteration in metoclopramide kinetics.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2050180     DOI: 10.1007/bf00265857

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

Review 1.  Drug disposition and liver disease.

Authors:  G R Wilkinson; S Schenker
Journal:  Drug Metab Rev       Date:  1975       Impact factor: 4.518

2.  Hepatofugal portal flow in cirrhosis: observations on hepatic hemodynamics and the nature of the arterioportal communications.

Authors:  W G Rector; J C Hoefs; K F Hossack; G T Everson
Journal:  Hepatology       Date:  1988 Jan-Feb       Impact factor: 17.425

Review 3.  Drug pharmacokinetics in cardiac and hepatic disease.

Authors:  R L Williams; L Z Benet
Journal:  Annu Rev Pharmacol Toxicol       Date:  1980       Impact factor: 13.820

4.  Altered serum protein binding of carbamazepine in disease states associated with an increased alpha 1-acid glycoprotein concentration.

Authors:  A Baruzzi; M Contin; E Perucca; F Albani; R Riva
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Bioavailability and disposition of metoclopramide after single- and multiple-dose administration in diabetic patients with gastroparesis.

Authors:  M E O'Connell; W M Awni; M Goodman; O Cass; A P Melikian; G J Wright; G R Matzke
Journal:  J Clin Pharmacol       Date:  1987-08       Impact factor: 3.126

Review 6.  Pharmacokinetics of high-dose metoclopramide in cancer patients.

Authors:  E M McGovern; J Grevel; S M Bryson
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of metoclopramide.

Authors:  D N Bateman
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

8.  Absolute bioavailability of metoclopramide given orally or by enema in patients with normal liver function or with cirrhosis of the liver.

Authors:  A Hellstern; D Hellenbrecht; R Saller; M Gatzen; B Manus; G Achtert; P Brockmann; H J Hausleiter; U Leuschner
Journal:  Arzneimittelforschung       Date:  1987-06

9.  Liquid chromatographic analysis of metoclopramide with fluorescence detection in cirrhotic patients.

Authors:  F Albani; R Riva; M Contin; A Baruzzi
Journal:  Biomed Chromatogr       Date:  1987       Impact factor: 1.902

Review 10.  Metoclopramide. An updated review of its pharmacological properties and clinical use.

Authors:  R A Harrington; C W Hamilton; R N Brogden; J A Linkewich; J A Romankiewicz; R C Heel
Journal:  Drugs       Date:  1983-05       Impact factor: 9.546

View more
  3 in total

1.  A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child-Pugh Classification.

Authors:  Julie Steelandt; Elodie Jean-Bart; Sylvain Goutelle; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2015-12       Impact factor: 6.447

2.  Pharmacokinetics of quinine in chronic liver disease.

Authors:  P Auprayoon; K Sukontason; K Na-Bangchang; V Banmairuroi; P Molunto; J Karbwang
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

Review 3.  Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.

Authors:  D J Morgan; A J McLean
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.